Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

Background— Rosiglitazone improves glycemic control for patients with type 2 diabetes mellitus, but there remains controversy regarding an observed association with cardiovascular hazard. The cardiovascular effects of rosiglitazone for patients with coronary artery disease remain unknown. Methods and Results— To examine any association between rosiglitazone use and cardiovascular events among patients with diabetes mellitus and coronary artery disease, we analyzed events among 2368 patients with type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Total mortality, composite death, myocardial infarction, and stroke, and the individual incidence of death, myocardial infarction, stroke, congestive heart failure, and fractures, were compared during 4.5 years of follow-up among patients treated with rosiglitazone versus patients not receiving a thiazolidinedione by use of Cox proportional hazards and Kaplan–Meier analyses that included propensity matching. After multivariable adjustment, among patients treated with rosiglitazone, mortality was similar (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.58–1.18), whereas there was a lower incidence of composite death, myocardial infarction, and stroke (HR, 0.72; 95% CI, 0.55–0.93) and stroke (HR, 0.36; 95% CI, 0.16–0.86) and a higher incidence of fractures (HR, 1.62; 95% CI, 1.05–2.51); the incidence of myocardial infarction (HR, 0.77; 95% CI, 0.54–1.10) and congestive heart failure (HR, 1.22; 95% CI, 0.84–1.82) did not differ significantly. Among propensity-matched patients, rates of major ischemic cardiovascular events and congestive heart failure were not significantly different. Conclusions— Among patients with type 2 diabetes mellitus and coronary artery disease in the BARI 2D trial, neither on-treatment nor propensity-matched analysis supported an association of rosiglitazone treatment with an increase in major ischemic cardiovascular events. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.

[1]  Mao Chen,et al.  Letter by Liu et al regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial". , 2014, Circulation.

[2]  M. Matheny,et al.  Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. , 2013, Journal of the American College of Cardiology.

[3]  M. Mitka.  Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. , 2013, JAMA.

[4]  V. Prasad,et al.  Prespecified falsification end points: can they validate true observational associations? , 2013, JAMA.

[5]  S. Yusuf,et al.  Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial , 2011, Diabetologia.

[6]  Rita Ouellet-Hellstrom,et al.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.

[7]  S. Nissen,et al.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.

[8]  Markolf Hanefeld,et al.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.

[9]  W. Boden,et al.  Therapies for Type 2 Diabetes and Coronary Artery Disease REPLY , 2009 .

[10]  M. Pfisterer,et al.  Therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[11]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[12]  B. Zinman,et al.  Thiazolidinediones and clinical outcomes in type 2 diabetes , 2009, The Lancet.

[13]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[14]  王晓燕.  Arch Intern Med:住院增加老年人出院后骨折危险 , 2009 .

[15]  W. Winkelmayer,et al.  Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. , 2008, Archives of internal medicine.

[16]  B. Zinman,et al.  Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.

[17]  L. Kennedy.  Rosiglitazone Evaluated for Cardiovascular Outcomes—An Interim Analysis , 2008 .

[18]  Sonal Singh,et al.  The safety of rosiglitazone in the treatment of type 2 diabetes. , 2008, Expert opinion on drug safety.

[19]  Tara Gomes,et al.  Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. , 2007, JAMA.

[20]  A. Kelly,et al.  Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus , 2007, Vascular medicine.

[21]  Sanjay Kaul,et al.  Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death , 2007, Annals of Internal Medicine.

[22]  C. Fang,et al.  Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience , 2007, Angiology.

[23]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[24]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[25]  C. Rosen.  The rosiglitazone story--lessons from an FDA Advisory Committee meeting. , 2007, The New England journal of medicine.

[26]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[27]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[28]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[29]  R. Frye,et al.  Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. , 2006, The American journal of cardiology.

[30]  D. Giugliano,et al.  Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. , 2006, Diabetes care.

[31]  H. Markus,et al.  Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[32]  Tzung-Dau Wang,et al.  Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.

[33]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[34]  A. Hamsten,et al.  Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[35]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[36]  J. R. Scotti,et al.  Available From , 1973 .